Corrigendum: Not always ‘squame’: The rare entity of follicular dendritic cell sarcoma of the tonsil presenting with cervical nodal metastases

No abstract available.

Follicular Dendritic Cell Sarcoma of the Thyroid Gland in a Patient with Preexisting Hashimoto’s Thyroiditis: A Rare Case Report with a Literature Review

Thyroid follicular dendritic cell sarcoma (FDCS) is an extremely rare malignancy that originates from follicular dendritic cells of the thyroid germinal centers. To the best of our knowledge, there are only 4 reported cases of thyroid FDCS in the English literature. Herein, we present the fifth case of FDCS of the thyroid gland. A 63-year-old woman presented with a painless midline neck mass, enlarging for the last 4 months. Physical examination revealed a 6-cm nonmobile, firm, multinodular thyroid mass with palpable cervical lymphadenopathy. Due to high suspicion for thyroid malignancy, the patient underwent total thyroidectomy with bilateral modified radical neck dissection. Histologic evaluations revealed sheets of storiform eosinophilic tumoral cells with prominent nucleoli containing multinucleated giant cells, and subsequent immunohistochemistry showed immunoreactivity for CD4, CD21, CD35, CD45 (LCA), and CD68. The patient was started on 6 cycles of doxorubicin, ifosfamide, and radiotherapy. She has had monthly thyroid ultrasonography and contrast-enhanced thoracoabdominal CT scan every 3 months for detecting potential recurrence and/or metastasis screening. Fortunately, 8 months after the operation, the patient is alive without any signs of local or distant metastasis.

Concomitant malignancies in the neck: follicular dendritic cell sarcoma; a rare tumour presenting as a right-sided neck nodal mass and papillary carcinoma thyroid

Follicular dendritic cell sarcoma is a rare low-grade sarcoma of mesenchymal origin. It involves the lymph nodes more commonly and rarely extranodal sites. The most common lymph node is cervical and usually presents as a painless asymptomatic mass. More often, it is a misdiagnosis, and there is a delay in treatment. It is rarely associated with Castleman disease, myasthenia gravis. Diagnosis of this condition is by histopathology and immunochemistry. Surgery is the primary modality of treatment, and adjuvant therapy has been tried with no definite trials due to the rarity of the disease. Here, we report a case of concomitant follicular dendritic sarcoma of the right cervical lymph node and papillary carcinoma of the thyroid managed in our institute. There was a line of investigations approaching towards a diagnosis, and she underwent total thyroidectomy and right modified radical neck dissection.

Follicular dendritic cell sarcoma of liver: a rare case report

Follicular dendritic cell sarcoma (FDCS) most commonly involves lymph nodes but also affects extranodal sites like liver, spleen, pancreas less commonly. It is a low to intermediate grade malignancy. Unusual presentation, morphology or immunophenotyping makes the diagnosis of FDCS very challenging. Immunohistochemistry plays a major role in confirming the diagnosis of FDCS. A 40 year male presented with dull abdominal pain. Ultrasonography revealed two hypoechoiec lesions in liver. Cytomorphology, later histological and immunohistochemistry (IHC) diagnosis of FDCS was established. Patient was put on chemotherapy.

Mimics of carcinoma: pancytokeratin positive follicular dendritic cell sarcoma

Introduction/Objective Follicular dendritic cell sarcoma (FDC-S) is a malignant neoplasm of follicular dendritic cells that can present with variable morphology including epithelioid and spindle cell components. Given its morphological diversity, FDC-S can mimic neoplasms including poorly differentiated carcinomas. Here we present a rare case of FDC-S in which immunohistochemical staining for pancytokeratin was focally positive, potentially leading to an erroneous diagnosis if a full spectrum of immunohistochemical stains was not considered. Methods/Case Report A 34-year-old man presented with an enlarging left neck mass, night sweats and fatigue that began approximately three months ago. CT scan showed a 5.6 x 4.2 x 3.7 cm necrotic mass in the left upper lateral carotid space. Histologic examination of the incisional biopsy specimen demonstrated portions of soft tissue comprised of pleomorphic and plump spindle cells forming whorls with no discernable node architecture (Panels A-B). The tumor cells are large with oval nuclei, vesicular chromatin, distinct nucleoli, and a moderate amount of eosinophilic cytoplasm. Occasional binucleated and multinucleated tumor cells, rare tumor cells with nuclear pseudoinclusions and atypical mitotic figures, and focal necrosis are identified. Scattered small mature lymphocytes are present. By immunohistochemistry, tumor cells are positive for pancytokeratin (focal) (Panel C), CD21 (panel D), CD23 (panel E), D2-40 (panel F), CD35 and clusterin, and negative for CD3, CD20, CD30, CD45, ALK-1, EMA, PAX5, PDL1 and S100 stains. The overall morphology and immunostaining pattern are compatible with follicular dendritic cell (FDC) sarcoma. Results (if a Case Study enter NA) NA Conclusion FDC sarcoma rarely occurs as the solitary mass in the head and neck region. The unusual focal positivity for pancytokeratin highlights the importance of comprehensive immunohistochemistry stains to confirm the diagnosis of FDC sarcoma since this case is focally positive for pancytokeratin, mimicking other neoplasms such as poorly differentiated carcinomas

Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review

BackgroundFollicular dendritic cell sarcoma (FDCS) is an uncommon malignant cancer, and there is no standard treatment to date. Resection followed by adjuvant chemotherapy or radiation is considered the most commonly used strategy for treatment. However, the treatment for patients who have progressed after systemic treatment is more controversial.Case summaryIn this case report, we describe a 57-year-old man with primary small intestine FDCS where surgery and second-line systemic chemotherapy failed. After disease progression (PD), the patient received sintilimab plus lenvatinib as third-line treatment and achieved a progression-free survival (PFS) with 7 months.ConclusionThis is the first report of a FDCS patient treated with immune checkpoint inhibitors (ICIs) and antiangiogenic agents, sintilimab and lenvatinib, as third-line therapy. Our case provides a potential therapeutic option for patients with FDCS who progressed after multiline therapy.